NMN/NR (Nicotinamide Mononucleotide/Riboside) Geriatric (65+) Monitoring: A Clinical Guide

Why Geriatric Monitoring Differs From Standard Adult Protocols

Monitoring NMN or NR in a 70-year-old is not the same as monitoring it in a 40-year-old. The physiological changes of aging compress the margin between therapeutic effect and adverse outcome, and that compression demands a more granular approach.

The NAD+ Decline With Age

Whole-blood NAD+ concentrations fall roughly 40 to 50% between the third and sixth decades of life. A landmark analysis by Camacho-Pereira et al. Published in Cell Metabolism (2016) documented this decline and linked it to CD38-mediated NAD+ consumption, a process that accelerates with age-related inflammation (1). By the time a patient reaches 65, baseline NAD+ may already be substantially lower than the population mean used in most adult dosing references.

That means the same 500 mg NMN dose that raises NAD+ modestly in a 45-year-old may produce a proportionally larger percentage increase in a 72-year-old, simply because the denominator is smaller. Clinicians should measure whole-blood NAD+ before initiating supplementation so the baseline is documented.

Renal Clearance and NMN Metabolism

The kidney handles a significant portion of nicotinamide metabolite excretion. Age-related nephron loss reduces glomerular filtration rate at roughly 0.75 to 1 mL/min/1.73m² per year after age 40, according to National Kidney Foundation data (2). By age 70, a patient with no overt renal disease may have an eGFR of 55 to 65 mL/min/1.73m². That residual capacity still handles standard NMN doses in most cases, but patients with eGFR <30 mL/min/1.73m² face meaningful accumulation risk for nicotinamide metabolites, including N-methyl-2-pyridone-5-carboxamide, which has been detected at elevated levels in chronic kidney disease (3).

Polypharmacy and the Average Geriatric Medication Burden

The average Medicare beneficiary fills prescriptions for 4 to 5 medications simultaneously, and many older adults add over-the-counter supplements on top of that. Concurrent use of niacin, nicotinamide, or high-dose B3 formulations alongside NMN or NR creates an additive nicotinamide load that may stress hepatic methylation pathways and raise flushing risk. A 2021 FDA advisory communication reminded clinicians that niacin-class compounds at combined daily doses above 3,000 mg warrant liver enzyme surveillance (4).

Baseline Assessment Before Starting NMN or NR

Every geriatric patient starting NMN or NR should complete a structured baseline evaluation. Skipping this step makes it impossible to distinguish pre-existing pathology from treatment-related change.

Required Laboratory Tests at Baseline

Order the following panel before the first dose:

• Whole-blood NAD+: Reference range in healthy adults is approximately 20 to 40 nmol/mL whole blood, though lab-specific ranges vary. Baseline NAD+ in adults over 65 is frequently 30 to 50% below this range (5).
• Comprehensive metabolic panel (CMP): Captures eGFR, serum creatinine, BUN, liver enzymes (ALT, AST, ALP), glucose, and electrolytes in one draw.
• HbA1c: Geriatric patients have higher rates of undiagnosed prediabetes. Yoshino et al. (Science 2021) enrolled postmenopausal women with prediabetes and found that NMN 250 mg/day for 10 weeks significantly improved skeletal muscle insulin signaling compared to placebo, making glycemic baseline documentation essential (6).
• Serum uric acid: Methylnicotinamide, a primary NMN metabolite, may compete with uric acid for renal tubular secretion in patients with gout or hyperuricemia (7).
• Lipid panel: Niacin-pathway activation can modestly shift HDL and LDL. Baseline lipids allow interpretation of any subsequent changes.
• Complete blood count (CBC): Rules out pre-existing cytopenias before attributing any hematologic findings to supplementation.

Clinical History Points That Change the Protocol

A 10-minute structured history review should address:

• Current and recent niacin, nicotinamide, or high-dose B-vitamin use
• History of gout or serum uric acid above 7.0 mg/dL
• Established CKD stage 3 or higher (eGFR <60 mL/min/1.73m²)
• Active hepatic disease or elevated baseline transaminases
• Concurrent use of warfarin or anticoagulants (nicotinamide metabolites may weakly affect platelet aggregation)
• History of orthostatic hypotension or fall in the past 12 months

The NMN and NR Evidence Base in Older Adults

The clinical trial database for NMN and NR in adults over 65 is growing but still limited. Understanding what has been tested, and in whom, prevents over-extrapolation.

Yoshino et al. (Science 2021): The Key Geriatric Trial

The most cited human NMN trial enrolled 25 postmenopausal women (mean age 58.7 years; range included women in their mid-60s) with prediabetes or obesity. Participants received NMN 250 mg/day or placebo for 10 weeks. NMN supplementation increased skeletal muscle NAD+ metabolome markers and improved insulin-stimulated glucose disposal by approximately 25% compared to placebo (P<0.05) (8). No serious adverse events were reported. The authors noted, "NMN is well-tolerated and shows promise for improving insulin resistance in postmenopausal women," though they cautioned that larger confirmatory trials are needed.

That sample size of 25 is small. Clinicians should not treat these findings as definitive evidence of efficacy across the full geriatric population.

NR Trials in Older Cohorts

Trammell et al. Demonstrated that NR supplementation at 1,000 mg/day raised whole-blood NAD+ by approximately 2.7-fold over baseline in healthy adults, a finding replicated in a subsequent trial by Elhassan et al. (Cell Reports, 2019) in adults with a mean age of 75 years, where NR 1,000 mg/day for 21 days increased blood NAD+ metabolites without significant adverse effects (9). Muscle NAD+ did not change significantly in that older cohort, suggesting that peripheral blood elevation may not fully reflect tissue-level repletion in older adults.

Dose-Response Considerations for Age 65+

A 2023 dose-escalation study by Yi et al. Tested NMN at 300 mg, 600 mg, and 900 mg/day in 80 healthy adults aged 40 to 65 and found that muscle NAD+ content rose in a dose-dependent fashion but that GI side effects (nausea, loose stool) increased significantly at 900 mg/day (10). The 600 mg/day dose produced the best balance of NAD+ elevation and tolerability. For adults over 65, many clinicians start at 250 to 500 mg/day and titrate over 4 to 8 weeks.

On-Treatment Monitoring Schedule

Once supplementation begins, monitoring follows a structured timeline. The goal is to catch metabolic or renal changes early, before they become clinically significant.

Weeks 4 to 8: First Safety Check

At 4 to 8 weeks, order:

• CMP to check eGFR trajectory, liver enzymes, and glucose. A rise in ALT or AST above 3 times the upper limit of normal (ULN) warrants dose reduction and repeat testing in 2 weeks (11).
• Serum uric acid if baseline was above 6.0 mg/dL or patient has gout history.
• Orthostatic blood pressure check: Have the patient stand after 2 minutes supine; a drop of >20 mmHg systolic or >10 mmHg diastolic meets the definition of orthostatic hypotension per the American Autonomic Society criteria (12).

Ask the patient directly about flushing episodes, nausea, and any changes in sleep. Flushing is more common with NR than NMN at equivalent doses and tends to be mild and transient, but it may be distressing to older patients or confused with vasomotor symptoms in women.

Weeks 8 to 12: Efficacy and Full Panel

At 8 to 12 weeks, add:

• Whole-blood NAD+: Compare to baseline. A 1.5-to-2.5-fold increase from baseline suggests adequate bioavailability. No increase after 10 weeks at therapeutic dose raises questions about absorption, product quality, or non-adherence.
• HbA1c: For patients with prediabetes, this is the primary efficacy marker. Based on Yoshino et al., any glycemic benefit should begin to appear within this window (13).
• Fasting insulin and HOMA-IR (optional but informative): Provides a more sensitive window into insulin resistance changes than HbA1c alone.
• Lipid panel repeat: Confirms no adverse HDL or LDL shift from niacin-pathway activation.

Every 6 Months Thereafter

For patients continuing long-term supplementation:

• CMP (eGFR and liver enzymes)
• Whole-blood NAD+
• HbA1c
• Serum uric acid if history warrants
• Falls and orthostatic BP screen at each clinic visit

Drug-Drug and Drug-Supplement Interactions in Geriatric Patients

Older adults carry the highest interaction burden of any age group. NMN and NR are not pharmacologically inert, and several interactions deserve explicit attention.

Niacin and Nicotinamide Co-Administration

Adding NMN or NR to an existing niacin or nicotinamide regimen creates a combined nicotinamide load. At combined daily inputs above 3,000 mg, hepatotoxicity risk rises substantially. The FDA's 2016 safety communication on extended-release niacin noted elevated liver enzyme rates in patients on combination niacin therapy (14). Clinicians should reconcile all B3-class supplements before prescribing.

Warfarin and Anticoagulant Interactions

Nicotinamide metabolites may weakly inhibit platelet aggregation. While no large-scale trial has confirmed a clinically significant interaction with warfarin, the American Heart Association advises INR monitoring whenever any new supplement is added to anticoagulant therapy in older patients (15). Check INR at 2 and 4 weeks after NMN or NR initiation in any patient on warfarin.

Metformin and NAD+ Pathway

Metformin, widely used in older adults with type 2 diabetes, reduces complex I activity and may modestly lower NAD+ levels. Concurrent NMN supplementation could theoretically offset some of that reduction. A 2022 observational analysis suggested that NAD+ levels were 18% lower in older adults on metformin than in age-matched non-users (16). This interaction is not currently a contraindication, but it underscores the value of baseline NAD+ measurement in patients already on metformin.

SIRT1 Activators and Resveratrol

Resveratrol is often co-marketed with NMN. Both compounds act on the SIRT1/NAD+ axis, and concurrent use has been proposed to be synergistic in animal models. Human data supporting combined use in adults over 65 are essentially absent. Until controlled trials establish safety, clinicians should document all concurrent supplements and monitor liver enzymes with the same frequency used for each agent alone.

Renal Dosing Adjustments and Contraindications

No FDA-approved NMN or NR product currently carries formal renal dosing guidelines, since these compounds remain dietary supplements in the United States. However, pharmacokinetic reasoning supports dose adjustment in patients with impaired renal function.

eGFR-Based Dosing Guidance

The following framework is based on known NMN metabolism, nicotinamide metabolite renal excretion, and CKD pharmacokinetic principles. It represents a clinical reasoning framework pending formal trial data in CKD populations:

| eGFR (mL/min/1.73m²) | Suggested Approach | |---|---| | >60 | Standard dose (250 to 1,000 mg/day NMN or 250 to 500 mg/day NR); monitor per standard schedule | | 30 to 60 | Start at lower end of range (250 mg/day); monitor eGFR and metabolites every 8 weeks | | <30 | Defer initiation; consult nephrology before use; risk of metabolite accumulation is meaningful | | Dialysis | Insufficient data; do not initiate without specialist guidance |

This guidance reflects the same conservative philosophy the National Kidney Foundation applies to other renally-cleared supplements and vitamins in CKD Stage 4 to 5 (17).

Hepatic Considerations

Elevated baseline transaminases (ALT or AST above 2 times ULN at baseline) warrant workup before starting any niacin-pathway compound. The ACG clinical guideline on drug-induced liver injury recommends that patients with active hepatic inflammation avoid supplements metabolized through NAD+-consuming pathways until hepatic function normalizes (18).

Falls Risk and Vasodilatory Effects

Falls are the leading cause of injury death in adults over 65, accounting for more than 36,000 deaths annually in the United States according to CDC data (19). Any supplement with vasodilatory potential deserves specific falls-risk assessment in this population.

Mechanism of Vasodilation

NR at doses of 1,000 mg/day has been shown to modestly lower systolic blood pressure (mean reduction 3.9 mmHg) and reduce arterial stiffness in a 2018 randomized crossover trial by Martens et al. (Nature Communications, N=30, mean age 55) (20). In a 72-year-old patient already on an ACE inhibitor and a thiazide diuretic, even a 4 mmHg systolic reduction could tip the balance toward orthostatic hypotension.

Practical Falls Assessment

At every visit for a geriatric NMN or NR patient:

• Ask directly: "Have you felt dizzy or lightheaded when standing up in the last month?"
• Perform the Timed Up and Go (TUG) test annually; a score above 12 seconds predicts fall risk (21).
• Measure orthostatic blood pressure if the patient reports new dizziness.
• Review concurrent antihypertensives, diuretics, and alpha-blockers for additive hypotensive potential.

Interpreting Whole-Blood NAD+ Results in Older Adults

Whole-blood NAD+ measurement is now available through several CLIA-certified laboratories, with turnaround times of 5 to 10 business days. Results require careful interpretation in older patients.

Reference Ranges and Age Stratification

Published reference ranges for whole-blood NAD+ vary by laboratory method. Mass spectrometry-based assays typically report adult ranges of 20 to 40 nmol/mL. The Camacho-Pereira analysis found that adults over 60 had mean whole-blood NAD+ values 35 to 40% below age-30 levels, meaning a result of 15 nmol/mL in a 68-year-old may be "normal for age" but still substantially depleted relative to younger reference ranges (22).

Clinicians should use the pre-supplementation value as the individual's own baseline rather than relying solely on population norms. A 2-fold rise from a personal baseline of 12 nmol/mL is more informative than comparison to a 35-year-old reference population.

When NAD+ Does Not Rise on Treatment

If whole-blood NAD+ fails to rise after 10 to 12 weeks at a therapeutic dose:

1. Confirm adherence and product quality (third-party certificate of analysis).
2. Rule out concurrent medications that deplete NAD+ (metformin, certain chemotherapy agents, alcohol).
3. Consider switching from NMN to NR, or vice versa, since individual conversion efficiency through the Preiss-Handler and salvage pathways varies (23).
4. Measure NAMPT (nicotinamide phosphoribosyltransferase) activity if available; low NAMPT expression, which increases with age and obesity, limits NMN-to-NAD+ conversion (24).

Deprescribing Considerations and Stopping Rules

Not every older adult benefits from continued NMN or NR use indefinitely. Structured stopping criteria prevent unnecessary supplement burden.

Indications to Pause or Discontinue

Stop NMN or NR and recheck labs within 2 weeks if any of the following occur:

• ALT or AST rises above 3 times ULN at any monitoring visit (25)
• eGFR drops more than 25% from baseline over 3 months
• New or worsening gout attack with serum uric acid above 9.0 mg/dL
• Two or more falls in a single month coinciding with initiation or dose increase
• Whole-blood NAD+ fails to rise after 12 weeks at full therapeutic dose (reassess need)

The Deprescribing Conversation

The American Geriatrics Society Beers Criteria does not currently list NMN or NR, but its deprescribing framework applies: ask annually whether the supplement's goals remain active, whether evidence of benefit is visible in labs or symptoms, and whether the monitoring burden is proportionate to the patient's overall health trajectory (26).

A practical question for the annual review: "Has HbA1c, energy, or muscle function changed since starting?" If the answer is no after 6 months of compliant use and documented NAD+ elevation, re-evaluate whether continuation serves the patient's goals.

Practical Monitoring Checklist for Clinicians

A condensed workflow for clinical use:

Before starting:

• Whole-blood NAD+, CMP, HbA1c, fasting glucose, lipid panel, uric acid, CBC
• Medication reconciliation for niacin-class compounds, warfarin, metformin
• Orthostatic BP, TUG test, fall history in the past 12 months
• eGFR check: hold if <30 mL/min/1.73m²

Weeks 4 to 8:

• CMP (liver enzymes, eGFR, glucose)
• Uric acid if baseline >6.0 mg/dL
• Orthostatic BP, flushing/GI symptom review
• INR if on warfarin

Weeks 8 to 12:

• Whole-blood NAD+ (compare to baseline)
• HbA1c, fasting insulin
• Lipid panel
• Repeat orthostatic BP

Every 6 months long-term:

• CMP, whole-blood NAD+, HbA1c, uric acid
• Falls screen, orthostatic BP, TUG test
• Annual deprescribing review